Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;10(1):3-23.
doi: 10.1007/s13193-018-0856-1. Epub 2019 Jan 3.

Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review

Paul H Sugarbaker  1
Affiliations

Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review

Paul H Sugarbaker. Indian J Surg Oncol. 2019 Mar.

Abstract

Peritoneal metastases may occur from a majority of cancers that occur within the abdomen or pelvis. When cancer spread to the peritoneal surfaces is documented, a decision regarding palliation versus an aggressive approach using cytoreductive surgery (CRS) and hyperthermic perioperative intraperitoneal chemotherapy (HIPEC) must be made. This decision is dependent on a well-defined group of prognostic indicators. In addition to treatment, prevention of peritoneal metastases may be an option. The clinical and pathologic features of a primary cancer can be used to select perioperative treatments that may prevent cancer cells within the abdomen and pelvis from progressing to established peritoneal metastases. In some clinical situations with appendiceal and colorectal cancers, the clinical or histopathologic features may indicate that second-look surgery plus perioperative chemotherapy should occur. Peritoneal metastases should always be considered by the multidisciplinary team for treatment or prevention.

Keywords: Appendiceal cancer; Cancer prevention; Colon cancer; Gastric cancer; Malignant peritoneal mesothelioma; Peritoneal metastases; Recurrent ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsThe author declares that he has no conflict of interest.

Figures

Fig. 1
Fig. 1
Pharmacokinetic study of mitomycin C
Fig. 2
Fig. 2
Anatomic sites of right colon cancer progression
Fig. 3
Fig. 3
Results of cytoreduction plus HIPEC compared to serial debulking procedures plus systemic chemotherapy or delayed intraperitoneal chemotherapy
See this image and copyright information in PMC

References

    1. Sugarbaker PH. New standard of care for appendiceal epithelial malignancies and pseudomyxoma peritonei syndrome. Lancet Oncol. 2006;7(1):69–76. - PubMed
    1. Sugarbaker PH, Turaga KK, Alexander HR, Jr, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016;12(10):928–935. - PubMed
    1. Colon cancer. Clinical practice guidelines in oncology (NCCN guidelines). Version 2.2017—March 13, 2017. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
    1. Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, Monk BJ, Chan JK. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33:1460–1466. - PMC - PubMed
    1. Sugarbaker PH, Kwong ML. Regional chemotherapy: possibilities for prevention and treatment of peritoneal metastases from gastric cancer. (In) Management of gastric cancer. SMGroup at www.smgbooks.com

LinkOut - more resources